In detail, genetic modification of CAR-Ts for the expression of IL-8 receptors (CXCR1 or CXCR2) and the utilization of the tumor-secreted IL-8 to usher the IL-8 receptor-modified CAR-Ts (IL-8R-CAR-Ts) to the tumor foci results in enhanced antitumor activity (84, 86). Here, CXCR2 is linked to neoplasm.